FTC About to Let Through a ‘Killer Acquisition’

In this Capitol Forum report, the merger of Roche and Spark Therapeutics, which could squash a cure for hemophilia while allowing Roche’s medication for it to thrive, is poised to be approved.

by

Fortify your mind! Join the Prospect today

Support The American Prospect's independent, nonprofit journalism by becoming a member today. You will stay engaged with the best and brightest political and public policy reporting and analyses, and help keep this website free from paywalls and open for all to read. Our membership levels offer a range of perks including an opt-in to receive the print magazine by mail.